Nasdaq · CIK 0001636651
OVID Ovid Therapeutics Inc.
Insider trading from SEC Form 4. Last filing Feb 28, 2025. Close $2.46 on Oct 9, 2026, +105% from the 52-week low and -17% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
6
with a Form 4 at this company
Price and insider trades, last year
OVIDOct 9, 2026 · close 2.46
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Ovid Therapeutics Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 20Weak | Margaret A. Alexander President and COO sell | $2,956 5,279 shares | -7% | - | |
| 26Weak | Margaret A. Alexander President and COO buy | $4,971 6,810 shares | +24% | - |
Transactions
The last 9 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 26, 2025 | Margaret A. Alexander President and COO | SOpen-market sale Common Stock | -5,279 | $0.56 | $2,956 | 73,406 | Feb 28, 2025 |
| Feb 20, 2025 | Margaret A. Alexander President and COO | AGrant or award Common Stock | +43,750 | $0.00 | $0 | 78,685 | Feb 24, 2025 |
| Feb 20, 2025 | Jeremy M Levin CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +1,650,000 | $0.00 | $0 | 1,650,000 | Feb 24, 2025 |
| Feb 20, 2025 | Margaret A. Alexander President and COO | AGrant or award Employee Stock Option (Right to Buy)derivative | +262,500 | $0.00 | $0 | 262,500 | Feb 24, 2025 |
| Jan 27, 2025 | Margaret A. Alexander President and COO | POpen-market purchase Common Stock | +6,810 | $0.73 | $4,971 | 34,935 | Jan 29, 2025 |
| Dec 12, 2024 | Karen Bernstein director | AGrant or award Stock Option (Right to Buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Dec 16, 2024 |
| Dec 12, 2024 | Barbara Gayle Duncan director | AGrant or award Stock Option (Right to Buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Dec 16, 2024 |
| Dec 12, 2024 | Kevin Joseph Fitzgerald director | AGrant or award Stock Option (Right to Buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Dec 16, 2024 |
| Dec 12, 2024 | Bart Friedman director | AGrant or award Stock Option (Right to Buy)derivative | +90,000 | $0.00 | $0 | 90,000 | Dec 16, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Margaret A. AlexanderPresident and COO
- Karen Bernsteindirector
- Barbara Gayle Duncandirector
- Kevin Joseph Fitzgeraldofficer, director
- Bart Friedmandirector
- Jeremy M LevinCEO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.